Lincoln Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr. Raja Karunanidhi Nagarajan as Senior General Manager- Research & Development (Designated as Senior Management Personnel ) of the Company with effect from 29th August, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has appointed Mr. Raja Karunanidhi Nagarajan as Senior General Manager – Research & Development, effective August 29, 2025. He has been designated as a Senior Management Personnel of the company. Mr. Nagarajan brings over 20 years of experience in pharmaceutical R&D, particularly in formulation and process development of generic products for US and EU regulated markets. He has previously worked at Torrent Research Center, Lupin Limited, and Cadila Pharmaceuticals Limited. The appointment has been disclosed under SEBI LODR Regulation 30.
This is a routine senior management appointment aimed at strengthening the company's R&D capabilities. It is not a board-level or key managerial change and is unlikely to have any immediate material impact on the stock price, though a strong R&D hire may support long-term product pipeline development.